American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Atara Biotherapeutics, Inc. (ATRA)

$8.55 +6.34% NASDAQ: ATRA · 15-min delayed

THOUSAND OAKS, California
Public · NASDAQ: ATRA
13 employees
Founded 2012

Visit website Follow

$89.4MMarket cap

$120.8MRevenue · FY2025

$32.7MNet income

13Employees

ATRANASDAQ

2014IPO

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Company facts

Founded: 2012
Type: Public · NASDAQ: ATRA
Employees: 13
IPO date: Oct 16, 2014
Headquarters: 1280 RANCHO CONEJO BLVD
THOUSAND OAKS, California 91320
Phone: 805-623-4211
Industry: Pharmaceuticals
Website: Visit site

Registry IDs

Ticker: ATRA Nasdaq
SEC CIK: 1604464
EIN: 460920988
SIC: 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Embed this company’s badge

Show Atara Biotherapeutics, Inc.’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/atara-biotherapeutics-inc/"><img src="https://americancompanies.com/badge/atara-biotherapeutics-inc.svg" alt="Atara Biotherapeutics, Inc. — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it, control the page, and earn the Verified badge.

Claim this profile

Track American companies

Create a free account to follow Atara Biotherapeutics, Inc. and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $120.8M
Net income: $32.7M
Total assets: $20.2M
Market cap: $89.4M
Operating margin: 29.7%
Net margin: 27.1%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

FY2021

FY2022

FY2023

FY2024

FY2025

Revenue Net income

FY 2025

Financial statements

Income statement

Revenue: $120.8M
Operating expenses: $84.9M
Operating income: $35.9M
Income tax: $31.0K
Net income: $32.7M
EPS (basic): $2.61
EPS (diluted): $2.57

Balance sheet

Total assets: $20.2M
Current assets: $12.2M
Total liabilities: $58.7M
Current liabilities: $14.9M
Shareholders’ equity: -$38.5M

Cash flow

Operating cash flow: -$50.9M
Investing cash flow: $18.1M
Financing cash flow: $16.1M
Net cash flow: -$16.7M

Statements via Polygon.io (SEC filings)

NASDAQ: ATRA

$8.55 +6.34%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$4.18 $18.09

52-week range

Market cap: $89.4M
P/E ratio: 3.3
EPS (diluted): $2.57
Shares outstanding: 10.5M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Oct 16, 2014

Atara Biotherapeutics, Inc. (ATRA) Stock Price

Profitable — net income of $32.7M in FY2025.
Revenue grew 494% from FY2021 to FY2025.
Trading 53% below its 52-week high.
Valued at a price-to-earnings (P/E) ratio of 3.3.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

Peers & competitors

Oric Pharmaceuticals, Inc.ORIC

No reviews yet. Be the first to review Atara Biotherapeutics, Inc..

Write a review

Newsroom

News about Atara Biotherapeutics, Inc.

ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA GlobeNewswire Inc. · 2026-05-19 · negative Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm GlobeNewswire Inc. · 2026-05-18 · negative DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions GlobeNewswire Inc. · 2026-05-14 · negative Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm GlobeNewswire Inc. · 2026-05-14 · negative ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm GlobeNewswire Inc. · 2026-05-14 · negative Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit GlobeNewswire Inc. · 2026-05-12 · negative

News & sentiment via Polygon.io

FAQ

Atara Biotherapeutics, Inc.: frequently asked questions

Is Atara Biotherapeutics, Inc. an American company?

Atara Biotherapeutics, Inc. is a US-based company headquartered in Thousand Oaks, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Atara Biotherapeutics, Inc. headquartered?

Atara Biotherapeutics, Inc. is headquartered in Thousand Oaks, California, United States.

Is Atara Biotherapeutics, Inc. publicly traded?

Yes — Atara Biotherapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol ATRA on the NASDAQ.

What does Atara Biotherapeutics, Inc. do?

Atara Biotherapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

When was Atara Biotherapeutics, Inc. founded?

Atara Biotherapeutics, Inc. was founded in 2012.

Explore